For an accessible version of this Press Release, please visit www.tevapharm.com
Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local currency terms compar...
Second quarter consolidated revenue declined 16% on lower industry demand
Second quarter diluted EPS at $0.34; adjusted diluted EPS at $0.38 ($0.52 in the second quarter of 2023)
Results reflect c...
